Florbetaben-PET detects amyloid in people with Down syndrome

July 11, 2013

A new study using PET with a florbetaben radiopharmaceutical shows how people with Down syndrome begin to accumulate beta-amyloid deposits in their brains in their early 40s, putting this population at greater risk for the early onset of cognitive impairment.

Researchers believe these findings also make people with Down syndrome a "unique population" to study the early evolution of beta amyloid and how it could lead to Alzheimer's disease, which, in turn, could help assess the effectiveness of amyloid-reducing therapies.